Leadership Overview
Gilead Sciences has 8 executives leading key functions including finance, marketing, supply chain, and research.
Driven by innovation, Gilead Sciences is dedicated to discovering, developing, and commercializing novel medicines for life-threatening diseases, aiming to improve patient care globally.
Driven by innovation, Gilead Sciences is dedicated to discovering, developing, and commercializing novel medicines for life-threatening diseases, aiming to improve patient care globally.
Leadership Roles at Gilead Sciences
Andrew Dickinson - Chief Financial Officer
Andrew Dickinson, the Chief Financial Officer at Gilead Sciences, directs all financial operations and strategic financial planning. Overseeing global finance departments, Dickinson ensures robust fiscal management across the company's biopharmaceutical endeavors, including the development and commercialization of treatments for HIV/AIDS, COVID-19, viral hepatitis, and oncology. This leadership role involves managing capital allocation, investor relations, and financial reporting to support the company's mission of addressing unmet medical needs. By optimizing financial strategies, Andrew Dickinson directly contributes to the sustainable growth and operational efficiency of Gilead Sciences. The Chief Financial Officer's oversight extends to financial risk assessment and the implementation of financial controls, safeguarding the company's assets and ensuring compliance with regulatory standards. Dickinson's financial acumen is critical for funding research and development initiatives, enabling the discovery of groundbreaking medicines.
Srihari Narasimhan - Strategic Initiatives Lead & To The Chief of Staff & Chief Financial Officer
Srihari Narasimhan, the Strategic Initiatives Lead & To The Chief of Staff & Chief Financial Officer at Gilead Sciences, drives key strategic projects and provides critical support to executive leadership. This multifaceted role involves identifying and developing new strategic opportunities that align with the company's mission to develop and commercialize innovative medicines for life-threatening diseases. Narasimhan works closely with the Chief of Staff and Chief Financial Officer to analyze market trends, assess potential collaborations, and implement initiatives that enhance operational efficiency and financial performance. The Strategic Initiatives Lead's focus extends to supporting the development of treatments for HIV/AIDS, COVID-19, viral hepatitis, and oncology. By bridging strategic planning with financial oversight, Srihari Narasimhan directly contributes to Gilead Sciences' growth and its ability to address critical global health challenges. This position is essential for navigating complex business landscapes and ensuring the successful execution of long-term corporate objectives.
Erik Schroeppel - Chief Marketing Officer, Supply Chain & Manager
Erik Schroeppel, the Chief Marketing Officer, Supply Chain & Manager at Gilead Sciences, drives market strategies and oversees critical supply chain operations. This dual-focused role ensures that Gilead's innovative medicines reach patients effectively while maintaining efficient and resilient supply networks. Schroeppel's marketing leadership involves developing and executing go-to-market plans for key therapeutic areas, including HIV/AIDS, viral hepatitis, and oncology treatments, aligning promotional efforts with scientific advancements and patient needs. Simultaneously, the supply chain management component focuses on optimizing logistics, manufacturing, and distribution to ensure product availability across the United States, Europe, and international markets. By integrating marketing insights with operational excellence, Erik Schroeppel enhances the company's market presence and patient access to vital therapies. The Chief Marketing Officer, Supply Chain & Manager's strategic direction supports the company's commitment to addressing significant global health challenges through its biopharmaceutical portfolio.
Sonja Tong - Executive Director and Chief of Staff
Sonja Tong, the Executive Director and Chief of Staff at Gilead Sciences, provides strategic support and operational leadership across key initiatives. This role involves coordinating efforts between executive leadership and various departments to advance the company's mission of developing novel medicines for life-threatening diseases. Tong's responsibilities include managing critical projects, facilitating cross-functional collaboration, and ensuring alignment with the company's strategic objectives in areas such as HIV/AIDS, COVID-19, viral hepatitis, and oncology. The Executive Director and Chief of Staff works closely with senior leaders to streamline decision-making processes and enhance organizational effectiveness. By driving strategic priorities and fostering efficient communication channels, Sonja Tong directly supports Gilead Sciences' commitment to innovation and patient care. This position is integral to translating high-level strategy into actionable plans that propel the development and commercialization of groundbreaking biopharmaceuticals.
Susanna Stinson - Director, Research Chief of Staff and Strategic Projects
Susanna Stinson, the Director, Research Chief of Staff and Strategic Projects at Gilead Sciences, spearheads critical initiatives within the research division. This role focuses on enhancing the efficiency and strategic direction of research and development efforts aimed at discovering and commercializing innovative medicines. Stinson oversees the management of key research projects, ensuring they align with Gilead's therapeutic priorities in areas such as HIV/AIDS, viral hepatitis, oncology, and inflammatory diseases. The Director, Research Chief of Staff and Strategic Projects facilitates collaboration among research teams and external partners, driving progress in the development of novel treatments. By providing strategic project oversight and operational support, Susanna Stinson directly contributes to advancing Gilead Sciences' pipeline and its mission to address significant unmet medical needs. This position is vital for translating scientific breakthroughs into tangible therapeutic solutions for patients worldwide.
Naomi Bautista - Gain Chief of Staff (Gilead Asian Interest Network)
Naomi Bautista, the Gain Chief of Staff (Gilead Asian Interest Network) at Gilead Sciences, leads initiatives focused on fostering diversity and inclusion within the organization. This role champions the goals of the Gilead Asian Interest Network, promoting cultural awareness and professional development opportunities for employees of Asian descent. Bautista works to enhance employee engagement and create a supportive environment that reflects Gilead's commitment to a diverse workforce. The Gain Chief of Staff collaborates with HR and leadership teams to implement programs that support the network's objectives and contribute to the company's broader diversity and inclusion strategy. By driving initiatives that strengthen employee networks and promote equitable practices, Naomi Bautista directly supports Gilead Sciences' values and its mission to improve global health through diverse perspectives. This position is key to building an inclusive culture that fuels innovation and collaboration.
Courtney Desmond - Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer
Courtney Desmond, the Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer at Gilead Sciences, provides essential operational and strategic support to the ethics and compliance functions. This role ensures that the company adheres to the highest ethical standards and regulatory requirements across all its biopharmaceutical operations. Desmond manages key projects and initiatives aimed at strengthening the compliance framework, overseeing areas such as drug development, marketing, and patient access to medicines. The Chief of Staff collaborates closely with the Chief Ethics and Compliance Officer to implement policies, conduct risk assessments, and promote a culture of integrity throughout the organization. By ensuring robust ethical practices and compliance, Courtney Desmond directly supports Gilead Sciences' commitment to responsible business conduct and patient trust. This position is critical for maintaining the company's reputation and its ability to operate effectively in regulated markets.
Brenda Hoffman - HIV Division
Brenda Hoffman, leading the HIV Division at Gilead Sciences, directs the strategic development and commercialization of therapies for HIV/AIDS. This critical role focuses on advancing Gilead's portfolio of life-saving treatments and ensuring patient access to these essential medicines across global markets. Hoffman oversees the lifecycle management of existing HIV medications and spearheads efforts to bring new, innovative therapies from research into clinical practice. The leadership within the HIV Division is dedicated to addressing the ongoing challenges of HIV prevention, treatment, and cure. By driving advancements in HIV therapeutics, Brenda Hoffman directly contributes to Gilead Sciences' long-standing commitment to combating the global HIV epidemic and improving the lives of millions affected by the virus. This division's work is central to the company's mission of transforming care for patients with life-threatening diseases.
Explore Leadership Teams in Manufacturing
Bristol-Myers Squibb operates as a global biopharmaceutical organization dedicated to discovering, developing, and manufacturing prescription medications that address serious patient needs across multiple therapeutic domains. The company's scientific expertise spans oncology, cardiovascular disease, immunoscience, and virology, with particular depth in treating complex conditions including HIV and cancer. Through sustained investment in research and development, the organization has built a comprehensive medication portfolio that combines innovative cancer immunotherapies, anticoagulant therapies, and treatments for chronic viral infections. The company's operational footprint extends across major markets worldwide, enabling efficient distribution and patient access to its therapeutic solutions. Bristol-Myers Squibb pursues a collaborative approach to medical innovation, actively engaging in research partnerships and strategic alliances that accelerate the development of new treatment options. This commitment to external collaboration complements the organization's internal capabilities, creating a dynamic environment where scientific breakthroughs can translate into meaningful therapeutic advances. Bristol-Myers Squibb's medication portfolio reflects decades of pharmaceutical expertise and a strategic focus on disease areas where unmet medical needs remain significant.
Company Leadership BG
NP
NC
Founded in 1969, Themis Medicar is a pharmaceutical company that specializes in manufacturing pharmaceuticals and medicinal chemicals for cardiology, pain management, anti-infectives, haematinics, and health and nutrition. Themis Medicare is located in India.
Company Leadership HM
TD
MS
RP
Unither Pharmaceuticals is a global contract development and manufacturing organization (CDMO) specializing in the production of single-dose liquid pharmaceuticals and sterile unit-dose formats for the pharmaceutical and consumer healthcare industries. The company is recognized as a world leader in blow-fill-seal technology, an advanced aseptic manufacturing process that forms, fills, and seals plastic containers in a continuous automated operation, ensuring high levels of sterility and product integrity. Unither's expertise encompasses the development and manufacturing of various liquid dosage forms including oral solutions, suspensions, nasal sprays, eye drops, and other sterile and non-sterile pharmaceutical products delivered in innovative single-dose formats. The company serves a diverse client base of pharmaceutical companies, biotechnology firms, and consumer health brands, providing comprehensive services from formulation development and clinical trial manufacturing to commercial-scale production and packaging. With manufacturing facilities strategically located across multiple continents including Europe and North America, Unither maintains strict quality standards and regulatory compliance with international pharmaceutical guidelines including FDA and EMA requirements. The company emphasizes innovation in drug delivery systems, patient convenience, and sustainability while helping clients bring their pharmaceutical products to market efficiently through its specialized manufacturing capabilities and technical expertise in unit-dose liquid formulations.
Company Leadership
ML
JK
GG
Getz Pharma is an international research-driven, branded generic pharmaceutical company specializing in the formulation, development, manufacturing and marketing of a wide range of quality, affordable medicines.
Company Leadership
HA
MB
AS
Frequently Asked Questions Regarding Gilead Sciences Top Executives and Leadership Team
Unlock more people and company data
